<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065775</url>
  </required_header>
  <id_info>
    <org_study_id>INDEX</org_study_id>
    <nct_id>NCT05065775</nct_id>
  </id_info>
  <brief_title>Bioavailability of Intranasal Dexmedetomidine</brief_title>
  <acronym>INDEX</acronym>
  <official_title>Intranasal Dexmedetomidine Pharmacokinetics on Patients Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to characterize the pharmacokinetics of dexmedetomidine in supine,&#xD;
      anesthetized adult patients after intranasal dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, intranasal dexmedetomidine pharmacokinetics have not been studied before on&#xD;
      anesthetized adult patients in supine position. As use of intranasal dexmedetomidine is&#xD;
      growing, it is crucial to enhance knowledge of its pharmacokinetics.&#xD;
&#xD;
      Open, exploratory study design will be used. Study population will consist of patients coming&#xD;
      to elective unilateral hip or knee arthroplasty under general anesthesia in Turku University&#xD;
      Hospital, Salo unit. Thirty patients compatible with the inclusion and exclusion criteria&#xD;
      will be entered into the study after receiving informed consent. Plasma concentrations of&#xD;
      dexmedetomidine and other significant data will be collected prospectively.&#xD;
&#xD;
      Intranasal dexmedetomidine 100 ug will be administered shortly after induction of general&#xD;
      anesthesia using a mucosal atomization (LMA MAD Nasal™) device, according to normal local&#xD;
      protocol. Second cannula will be placed after patient is anesthetized, in order to obtain&#xD;
      blood samples. Venous blood samples will be obtained immediately prior to administration of&#xD;
      dexmedetomidine (baseline) and thereafter at 5, 15, 45 min and 1, 4 h into EDTA tubes for&#xD;
      determination of dexmedetomidine, and possibly adrenaline and noradrenaline plasma&#xD;
      concentrations.&#xD;
&#xD;
      Vital signs (heart rate, blood pressure and peripheral oxygen saturation) will be followed&#xD;
      during the operation, as well as in the post anesthesia care unit according to the local&#xD;
      protocol. Before patients will be admitted to the ward, they are expected to be appropriately&#xD;
      arousable and have vital signs in normal limits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability (%) of intranasally given dexmedetomidine</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Arthritis Knee</condition>
  <condition>Arthritis of Hip</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intranasal 100 µg bolus dose of dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is scheduled for elective unilateral total knee arthroplasty or hip&#xD;
             arthroplasty under general anesthesia&#xD;
&#xD;
          -  Fluent skills in finnish language (to understand the given information and to be able&#xD;
             to give informed consent and communicate with the study personnel)&#xD;
&#xD;
          -  Age between 35 and 80 years&#xD;
&#xD;
          -  Weight between 50 and 100 kg&#xD;
&#xD;
          -  ASA (American Society of Anesthesiologists) status 1-3&#xD;
&#xD;
          -  Written informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A previous history of intolerance to the study drug or related compounds and additives&#xD;
&#xD;
          -  Disease or condition affecting patient's ability to give written informed consent&#xD;
&#xD;
          -  Existing or recent significant disease possible affecting absorption, distribution,&#xD;
             metabolism, excretion or response to the study drug&#xD;
&#xD;
          -  History of cardiac disease (valvular insufficiency, severe left ventricular&#xD;
             dysfunction) or abnormal ECG rhythm (bradycardia &lt; 50/min, 2nd or 3rd degree&#xD;
             atrio-ventricular block, pacemaker)&#xD;
&#xD;
          -  Chronic opioid use or use of other analgesic adjuvants such as pregabalin, gabapentin,&#xD;
             amitriptyline or duloxetine&#xD;
&#xD;
          -  Participation in any other study concomitantly or within one month prior to the entry&#xD;
             into this study&#xD;
&#xD;
          -  Clinically significant abnormal findings in physical examination or laboratory&#xD;
             screening&#xD;
&#xD;
          -  Use of drugs or natural products known to cause enzyme induction or inhibition&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Spinal anesthesia&#xD;
&#xD;
          -  Preoperative systolic blood pressure &lt;110 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panu Uusalo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku and Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panu Uusalo, MD, PhD</last_name>
    <phone>+358405374426</phone>
    <email>panu.uusalo@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teijo Saari, MD, PhD</last_name>
    <phone>+35823130651</phone>
    <email>teisaa@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital and University of Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Teijo Saari, MD, PhD</last_name>
      <email>teisaa@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuula Manner, MD, PhD</last_name>
      <email>tuula.manner@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Suvi Tiainen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Panu Uusalo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

